Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jan;35(1):8–13. doi: 10.1111/j.1365-2125.1993.tb05663.x

A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

T C Li Kam Wa 1, E D Cooke 1, P Turner 1
PMCID: PMC1381483  PMID: 8448072

Abstract

1. The effects of captopril and enalapril on skin responses to intradermal injections of bradykinin and skin blood flow in the forearm were investigated in this randomised, double-blind, placebo-controlled, cross-over study. 2. Intradermal injections of 0, 1, 2.5 and 5 micrograms of bradykinin in 0.9% sodium chloride were made into the forearm of twelve healthy volunteers before and at 2, 6 and 24 h after single oral doses of 25 mg captopril, 10 mg enalapril or placebo. Forearm skin blood flow was measured by the technique of laser Doppler flowmetry (LDF) before the injections were made and the skin responses evaluated at 15 min after injections of bradykinin by measurement of cutaneous blood flow outside the induced weal, erythema area and weal volume. 3. The bradykinin-induced cutaneous responses measured by LDF, erythema area and weal volume increased with incremental bradykinin dose. Compared with placebo, captopril significantly augmented the cutaneous vasodilator effects of bradykinin, measured by LDF and erythema area, at 2 h and the weal responses at 2 and 6 h. Enalapril enhanced the vasodilator responses to bradykinin at 2 and 6 h and the weal responses at 2, 6 and 24 h. Neither captopril nor enalapril significantly affected forearm skin blood flow. 4. This study showed that captopril and enalapril potentiated the effects of intradermal bradykinin both with respect to blood flow changes and weal formation in keeping with effective kininase II inhibition and the time course of these changes are consistent with enalapril being a longer acting drug than captopril. Captopril and enalapril exerted no influence on forearm skin blood flow measured by LDF.

Full text

PDF
8

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benjamin N., Cockcroft J. R., Collier J. G., Dollery C. T., Ritter J. M., Webb D. J. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989 May;412:543–555. doi: 10.1113/jphysiol.1989.sp017630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Biollaz J., Burnier M., Turini G. A., Brunner D. B., Porchet M., Gomez H. J., Jones K. H., Ferber F., Abrams W. B., Gavras H. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther. 1981 May;29(5):665–670. doi: 10.1038/clpt.1981.92. [DOI] [PubMed] [Google Scholar]
  3. Breckenridge A. Angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) 1988 Feb 27;296(6622):618–620. doi: 10.1136/bmj.296.6622.618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Colardyn F., Clement D. L. Differential effects of vasodilators on forearm and calf vessels. Angiology. 1990 Apr;41(4):313–317. doi: 10.1177/000331979004100408. [DOI] [PubMed] [Google Scholar]
  5. Cook J., Shuster S. Histamine weal formation and absorption in man. Br J Pharmacol. 1980 Aug;69(4):579–585. doi: 10.1111/j.1476-5381.1980.tb07907.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crantz F. R., Swartz S. L., Hollenberg N. K., Moore T. J., Dluhy R. G., Williams G. H. Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension. Hypertension. 1980 Sep-Oct;2(5):604–609. doi: 10.1161/01.hyp.2.5.604. [DOI] [PubMed] [Google Scholar]
  7. Creager M. A., Faxon D. P., Rockwell S. M., Melby J. C., Gavras H., Coffman J. D. Effect of renin-angiotensin system on limb circulation in normal subjects. Am J Physiol. 1984 Feb;246(2 Pt 2):H239–H244. doi: 10.1152/ajpheart.1984.246.2.H239. [DOI] [PubMed] [Google Scholar]
  8. Faxon D. P., Creager M. A., Halperin J. L., Bernard D. B., Ryan T. J. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure. Am J Med. 1984 May 31;76(5B):104–110. doi: 10.1016/0002-9343(84)90895-7. [DOI] [PubMed] [Google Scholar]
  9. Ferguson R. K., Turini G. A., Brunner H. R., Gavras H., McKinstry D. N. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977 Apr 9;1(8015):775–778. doi: 10.1016/s0140-6736(77)92958-0. [DOI] [PubMed] [Google Scholar]
  10. Ferner R. E., Simpson J. M., Rawlins M. D. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) 1987 May 2;294(6580):1119–1120. doi: 10.1136/bmj.294.6580.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fuller R. W., Warren J. B., McCusker M., Dollery C. T. Effect of enalapril on the skin response to bradykinin in man. Br J Clin Pharmacol. 1987 Jan;23(1):88–90. doi: 10.1111/j.1365-2125.1987.tb03014.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Given B. D., Taylor T., Hollenberg N. K., Williams G. H. Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):436–441. doi: 10.1097/00005344-198405000-00010. [DOI] [PubMed] [Google Scholar]
  13. Holloway G. A., Jr, Watkins D. W. Laser Doppler measurement of cutaneous blood flow. J Invest Dermatol. 1977 Sep;69(3):306–309. doi: 10.1111/1523-1747.ep12507665. [DOI] [PubMed] [Google Scholar]
  14. Hulthén L., Hökfelt B. The effect of the converting enzyme inhibitor SQ 20.881 on kinins, renin-angiotensin-aldosterone and catecholamines in relation to blood pressure in hypertensive patients. Acta Med Scand. 1978;204(6):497–502. doi: 10.1111/j.0954-6820.1978.tb08479.x. [DOI] [PubMed] [Google Scholar]
  15. Johnston C. I., Clappison B. H., Anderson W. P., Yasujima M. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol. 1982 Apr 21;49(6):1401–1404. doi: 10.1016/0002-9149(82)90350-2. [DOI] [PubMed] [Google Scholar]
  16. Johnston M. G., Hay J. B., Movat H. Z. The modulation of enhanced vascular permeability by prostaglandins through alterations in blood flow (hyperemia). Agents Actions. 1976 Nov;6(6):705–711. doi: 10.1007/BF02026092. [DOI] [PubMed] [Google Scholar]
  17. Li Kam Wa T. C., Almond N. E., Cooke E. D., Turner P. Effect of captopril on skin blood flow following intradermal bradykinin measured by laser Doppler flowmetry. Eur J Clin Pharmacol. 1989;37(5):471–475. doi: 10.1007/BF00558126. [DOI] [PubMed] [Google Scholar]
  18. Li Kam Wa T. C., Almond N. E., Cooke E. D., Turner P. Skin blood flow changes following intradermal bradykinin injections measured by laser Doppler flowmetry: comparison with weal and flare. J Med Eng Technol. 1990 Sep-Oct;14(5):190–193. doi: 10.3109/03091909009009959. [DOI] [PubMed] [Google Scholar]
  19. Nilsson G. E., Tenland T., Oberg P. A. Evaluation of a laser Doppler flowmeter for measurement of tissue blood flow. IEEE Trans Biomed Eng. 1980 Oct;27(10):597–604. doi: 10.1109/TBME.1980.326582. [DOI] [PubMed] [Google Scholar]
  20. Odya C. E., Wilgis F. P., Walker J. F., Oparil S. Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421). J Lab Clin Med. 1983 Nov;102(5):714–721. [PubMed] [Google Scholar]
  21. Rasmussen S., Hesse B., Bonde-Petersen F., Damkjaer Nielsen M., Christensen N. J., Giese J., Warberg J. Haemodynamic and humoral effects of lower body negative pressure in normal, sodium-replete man during angiotensin-converting enzyme inhibition with captopril. Scand J Clin Lab Invest. 1986 Feb;46(1):81–88. doi: 10.3109/00365518609086485. [DOI] [PubMed] [Google Scholar]
  22. Rustin M. H., Almond N. E., Beacham J. A., Brooks R. J., Jones D. P., Cooke E. D., Dowd P. M. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol. 1987 Dec;117(6):751–758. doi: 10.1111/j.1365-2133.1987.tb07356.x. [DOI] [PubMed] [Google Scholar]
  23. Semple P. F., Herd G. W. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med. 1986 Jan 2;314(1):61–61. doi: 10.1056/NEJM198601023140119. [DOI] [PubMed] [Google Scholar]
  24. Serup J. Diameter, thickness, area, and volume of skin-prick histamine weals. Measurement of skin thickness by 15 MHz A-mode ultrasound. Allergy. 1984 Jul;39(5):359–364. doi: 10.1111/j.1398-9995.1984.tb01953.x. [DOI] [PubMed] [Google Scholar]
  25. Sesoko S., Kaneko Y. Cough associated with the use of captopril. Arch Intern Med. 1985 Aug;145(8):1524–1524. [PubMed] [Google Scholar]
  26. Stern M. D., Lappe D. L., Bowen P. D., Chimosky J. E., Holloway G. A., Jr, Keiser H. R., Bowman R. L. Continuous measurement of tissue blood flow by laser-Doppler spectroscopy. Am J Physiol. 1977 Apr;232(4):H441–H448. doi: 10.1152/ajpheart.1977.232.4.H441. [DOI] [PubMed] [Google Scholar]
  27. Swartz S. L., Williams G. H. Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol. 1982 Apr 21;49(6):1405–1409. doi: 10.1016/0002-9149(82)90351-4. [DOI] [PubMed] [Google Scholar]
  28. Swartz S. L., Williams G. H., Hollenberg N. K., Crantz F. R., Moore T. J., Levine L., Sasahara A. A., Dluhy R. G. Endocrine profile in the long-term phase of converting-enzyme inhibition. Clin Pharmacol Ther. 1980 Oct;28(4):499–508. doi: 10.1038/clpt.1980.194. [DOI] [PubMed] [Google Scholar]
  29. Todd P. A., Heel R. C. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986 Mar;31(3):198–248. doi: 10.2165/00003495-198631030-00002. [DOI] [PubMed] [Google Scholar]
  30. Vinci J. M., Horwitz D., Zusman R. M., Pisano J. J., Catt K. J., Keiser H. R. The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension. 1979 Jul-Aug;1(4):416–426. doi: 10.1161/01.hyp.1.4.416. [DOI] [PubMed] [Google Scholar]
  31. Webb D. J., Collier J. G., Seidelin P. H., Struthers A. D. Regulation of regional vascular tone: the role of angiotensin conversion in human forearm resistance vessels. J Hypertens Suppl. 1988 Dec;6(3):S57–S59. [PubMed] [Google Scholar]
  32. Williams T. J., Peck M. J. Role of prostaglandin-mediated vasodilatation in inflammation. Nature. 1977 Dec 8;270(5637):530–532. doi: 10.1038/270530a0. [DOI] [PubMed] [Google Scholar]
  33. Wood S. M., Mann R. D., Rawlins M. D. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) 1987 Jan 10;294(6564):91–92. doi: 10.1136/bmj.294.6564.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yang H. Y., Erdös E. G., Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 1970 Aug 21;214(2):374–376. doi: 10.1016/0005-2795(70)90017-6. [DOI] [PubMed] [Google Scholar]
  35. van Leeuwen B. H., Millar J. A., Hammat M. T., Johnston C. I. Radioimmunoassay of blood bradykinin: purification of blood extracts to prevent cross-reaction with endogenous kininogen. Clin Chim Acta. 1983 Feb 7;127(3):343–351. doi: 10.1016/0009-8981(83)90161-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES